News
CBIO
13.65
+0.81%
0.11
Weekly Report: what happened at CBIO last week (1026-1030)?
Weekly Report · 11/02 09:38
Crescent Biopharma (CBIO) Gets a Buy from H.C. Wainwright
TipRanks · 10/28 08:26
Crescent Biopharma (CBIO) Gets a Buy from Piper Sandler
TipRanks · 10/26 11:45
Weekly Report: what happened at CBIO last week (1019-1023)?
Weekly Report · 10/26 09:38
Crescent Biopharma: Buy Rating Reiterated as CR-001 Program Advances; 12-Month Price Target Maintained at $36
TipRanks · 10/19 10:35
Crescent Biopharma Price Target Maintained With a $36.00/Share by HC Wainwright & Co.
Dow Jones · 10/19 10:29
Weekly Report: what happened at CBIO last week (1012-1016)?
Weekly Report · 10/19 09:38
Crescent Biopharma (CBIO) Receives a New Rating from Wedbush
TipRanks · 10/16 13:05
Analysts Offer Insights on Healthcare Companies: McKesson (MCK), Crescent Biopharma (CBIO) and Glaukos (GKOS)
TipRanks · 10/16 12:20
Crescent Biopharma advances oncology pipeline and ADC programs
TipRanks · 10/15 20:48
Crescent Biopharma Says Global Phase 1/2 APOLLO Trial Of CR-002, a PD-L1-Targeted ADC, On Track To Commence Dosing This Quarter; Initial Data Expected In H2 2027; Phase 1/2 Trial Of CR-003 (SKB105), An ITGB6-Targeted ADC, Ongoing In China; Initial Data Expected In Q1 2027
Benzinga · 10/15 20:31
Crescent Biopharma completes dose escalation in ASCEND trial of CR-001
TipRanks · 10/15 20:25
Weekly Report: what happened at CBIO last week (1005-1009)?
Weekly Report · 10/12 09:40
HC Wainwright & Co. Upgrades Crescent Biopharma to Buy from Neutral
NASDAQ · 10/06 15:39
Crescent Biopharma Announces Grants of Inducement Awards
Barchart · 10/06 15:15
Crescent Biopharma (CBIO) Gets a Buy from Stifel Nicolaus
TipRanks · 10/06 10:58
Crescent Biopharma Raised to Buy From Neutral by HC Wainwright & Co.
Dow Jones · 10/06 10:27
Crescent Biopharma Price Target Announced at $36.00/Share by HC Wainwright & Co.
Dow Jones · 10/06 10:27
HC Wainwright & Co. Upgrades Crescent Biopharma to Buy, Announces $36 Price Target
Benzinga · 10/06 10:18
Crescent Biopharma upgraded to Buy from Neutral at H.C. Wainwright
TipRanks · 10/06 10:15
More
Webull provides a variety of real-time CBIO stock news. You can receive the latest news about Crescent Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About CBIO
Crescent Biopharma, Inc. is a biotechnology company. The Company is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.